<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519827</url>
  </required_header>
  <id_info>
    <org_study_id>CHARM-01-2020</org_study_id>
    <nct_id>NCT04519827</nct_id>
  </id_info>
  <brief_title>A Hypoallergenicity Study on a New Rice-Based Hydrolysate Formula</brief_title>
  <acronym>CHARM</acronym>
  <official_title>A Prospective, Randomised, Double-blind Controlled Study, to Evaluate the Safety/Hypoallergenicity of a New Rice-based Hydrolysate Formula With New Ingredient for Infants and Children With Diagnosed Cow's Milk Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Schär AG / SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Schär AG / SPA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cow's Milk Allergy (CMA) affects between 2-3% of young children but its severity varies&#xD;
      between regions/countries. While the long-term prognosis for CMA is good, with the majority&#xD;
      (80-90%) of children outgrowing their allergy by around 3-5 years. Breast feeding is the most&#xD;
      optimal form of feeding for all infants, regardless of their condition, and in those with CMA&#xD;
      maternal dairy exclusion is recommended as first line treatment. In non-breast fed or mixed&#xD;
      feeding, a hypoallergenic milk substitute is recommended for young infants. The AAP and other&#xD;
      societies such as EAACI and ESPGHAN considers a formula to be 'hypoallergenic' if at least&#xD;
      90% of children with documented CMA tolerate it, with a 95% CI, under double-blind,&#xD;
      placebo-controlled conditions.This equates to at least 29 children who should tolerate the&#xD;
      product following blind and open challenge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multi-centre double blind randomised placebo-controlled study to demonstrate&#xD;
      the safety and tolerance of a new rice-based hydrolysate in children with diagnosed Cow's&#xD;
      Milk Allergy (CMA). The test product being a new milk substitute hydrolysed rice-based&#xD;
      formula with new ingredient. The results will satisfy the safety requirement when tolerated&#xD;
      by 90% of children with proven CMA, with a confidence of 95%. New, and previously diagnosed&#xD;
      children with confirmed CMA who meet the inclusion criteria will be eligible to participate&#xD;
      in the study. Those included in the intervention phase will have IgE testing and an oral food&#xD;
      challenge (OFC) to test and placebo products, in a randomised double-blind design. Children&#xD;
      with a negative reaction to both test and placebo products will receive the test product for&#xD;
      a period of 7 days (open challenge).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoallergenicity</measure>
    <time_frame>7 days open challenge</time_frame>
    <description>90% of children tolerate the TEST formula with a 95% CI - using the double blind placebo controlled food challenge and open challenge (Test vs. placebo).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Allergy;Food</condition>
  <arm_group>
    <arm_group_label>New Rice-based hydrolysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The TEST formula is a new Rice-based hydrolysate with new ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amino-acid based formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The PLACEBO is an Amino-acid based formula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>New Rice-based hydrolysate</intervention_name>
    <description>A rice-based hydrolysed infant formula with new ingredient</description>
    <arm_group_label>New Rice-based hydrolysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amino Acid-based infant formula</intervention_name>
    <description>An amino acid-based infant formula</description>
    <arm_group_label>Amino-acid based formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children &lt;10 yrs of age&#xD;
&#xD;
          2. Proven IgE-mediated CMA&#xD;
&#xD;
          3. &gt;2500g at birth&#xD;
&#xD;
          4. &gt; 37 weeks gestation&#xD;
&#xD;
          5. Written informed consent provided by parent(s)/guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infants/children with severe concurrent illness (other than food allergy/CMA)&#xD;
&#xD;
          2. Investigator's uncertainty about the willingness or ability of the subject to comply&#xD;
             with the protocol requirements.&#xD;
&#xD;
          3. Participation in other studies involving use of milk replacement products designed to&#xD;
             treat/manage CMA within two weeks prior to entry into this study&#xD;
&#xD;
          4. Current participation in OIT to Cow's Milk&#xD;
&#xD;
          5. Diagnosis of anaphylaxis to Cow's Milk&#xD;
&#xD;
          6. Diagnosis of rice allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion Meraner</last_name>
    <phone>+39 0473 293 648</phone>
    <email>Marion.Meraner@drschar-medical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meyer Children's Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof F. Mori</last_name>
      <email>francesca.mori@meyer.it</email>
    </contact>
    <contact_backup>
      <last_name>Dr G. Liccioli</last_name>
      <email>giulia.liccioli@meyer.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Infantile Regina Margherita.</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof G Monti</last_name>
    </contact>
    <contact_backup>
      <last_name>Dr R Calzedda</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu Barcelona 2020,</name>
      <address>
        <city>Barcelona</city>
        <zip>08950 Esplugues de Llobregat,</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof M Alvaro</last_name>
    </contact>
    <contact_backup>
      <last_name>Dr M Sandoval</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cow's Milk Protein Allergy (CMPA)</keyword>
  <keyword>Cow's Milk Allergy (CMA)</keyword>
  <keyword>CHILDREN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

